PetVivo Holdings Inc. Announces Participation in The ThinkEquity Conference
- PetVivo Holdings, Inc. will be participating in The ThinkEquity Conference on October 19, 2023.
- John Lai, CEO of PetVivo Holdings, Inc., will provide an overview of the company and its lead product, SPRYNG™ with OsteoCushion™ Technology.
- None.
Minneapolis, Minnesota--(Newsfile Corp. - October 9, 2023) - PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York. John Lai, Chief Executive Officer of PetVivo Holdings, Inc. will be presenting in the South Salon II of the Mandarin Oriental Hotel from 3:00 PM to 3:30 PM EDT on October 19th. Interested parties can register to attend here. Members of the PetVivo Holdings, Inc. management will also be holding one-on-one investor meetings throughout the day. Mr. Lai intends to provide an overview of PetVivo Holdings, Inc. as well as discuss its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles; Spryng microparticles perform in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis. For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact info1@petvivo.com or visit https://petvivo.com/ and https://sprynghealth.com/.
John Lai will be presenting at 3 pm ET on October 19th. Interested parties can register to attend here. Members of the PetVivo Holdings Inc. management will also be holding one-on-one investor meetings throughout the day.
About Petvivo Holdings Inc
PetVivo Holdings Inc. (NASDAQ: PETV) (NASDAQ: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. The Company has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint-related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.
About The ThinkEquity Conference
The ThinkEquity Conference will gather industry insiders, investors and leading executives from around the world on October 19th in New York. Attendees can expect a full day of company presentations, one-on-one investor meetings, networking and more.
Featured sectors include AI, Technology, Biotechnology, EV/EV Infrastructure, Metals & Mining and Energy.
To register to attend The ThinkEquity Conference, please follow this link.
For further information:
JOHN LAI
6123284325
jlai@petvivo.com
Source: PetVivo Holdings Inc
FAQ
When is The ThinkEquity Conference?
Who will be presenting from PetVivo Holdings, Inc.?
What is SPRYNG™ with OsteoCushion™ Technology?
